Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cells ; 8(8)2019 08 09.
Article in English | MEDLINE | ID: mdl-31405017

ABSTRACT

Glioblastoma multiforme is the most aggressive malignant tumor of the central nervous system. Due to the absence of effective pharmacological and surgical treatments, the identification of early diagnostic and prognostic biomarkers is of key importance to improve the survival rate of patients and to develop new personalized treatments. On these bases, the aim of this review article is to summarize the current knowledge regarding the application of molecular biology and proteomics techniques for the identification of novel biomarkers through the analysis of different biological samples obtained from glioblastoma patients, including DNA, microRNAs, proteins, small molecules, circulating tumor cells, extracellular vesicles, etc. Both benefits and pitfalls of molecular biology and proteomics analyses are discussed, including the different mass spectrometry-based analytical techniques, highlighting how these investigation strategies are powerful tools to study the biology of glioblastoma, as well as to develop advanced methods for the management of this pathology.


Subject(s)
Biomarkers, Tumor/analysis , Glioblastoma/diagnosis , Neoplasm Proteins/analysis , Proteomics , Animals , Humans , Molecular Biology
2.
Drug Deliv ; 22(3): 276-85, 2015 May.
Article in English | MEDLINE | ID: mdl-24437962

ABSTRACT

Targeted drug delivery for brain tumor treatment is one of the important objectives in nanomedicine. Human glioblastoma is the most frequent and aggressive type of brain tumors. The preferential expression of membrane protein connexin 43 (Cx43) and brain-specific anion transporter (BSAT1) in the tumor and peritumoral area is a key component for targeted drug delivery. The purpose of this study was to design cisplatin-loaded nanogels conjugated with monoclonal antibodies to Cx43 and BSAT1 for treatment of intracranial gliomas 101/8. MRI volumetric analysis of tumor-bearing rats indicated significantly reduced tumor volume with cisplatin-loaded targeted-nanogel treatment compared to other formulations. The median survival of rats treated with targeted nanogels conjugated with specific mAbs against extracellular loops of Cx43 and BSAT1 were 27 and 26.6 days higher than that in control group, respectively. For the first time we demonstrated the efficiency of mAb-targeted cisplatin-loaded nanogels in the experimental model of glioma 101/8. This approach could facilitate the development of new drug delivery systems for the treatment of gliomas.


Subject(s)
Antibodies, Monoclonal/chemistry , Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Cisplatin/therapeutic use , Connexin 43/antagonists & inhibitors , Drug Carriers/chemistry , Glioblastoma/drug therapy , Organic Cation Transport Proteins/antagonists & inhibitors , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacokinetics , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Cell Line, Tumor , Cell Survival/drug effects , Cisplatin/administration & dosage , Cisplatin/pharmacokinetics , Female , Gels/chemistry , Glioblastoma/metabolism , Glioblastoma/pathology , Nanostructures/chemistry , Neoplasm Transplantation , Rats, Wistar , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...